MedPath

Amoxicillin

Generic Name
Amoxicillin
Brand Names
Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
Drug Type
Small Molecule
Chemical Formula
C16H19N3O5S
CAS Number
26787-78-0
Unique Ingredient Identifier
9EM05410Q9
Background

Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication

Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions
Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
Clinical Trials
Related News

The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-08-13
Last Posted Date
2013-12-03
Lead Sponsor
Yuhan Corporation
Target Recruit Count
95
Registration Number
NCT01921647
Locations
🇰🇷

Yonsei University Severance Hospital, Seoul, Korea, Republic of

The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication

Phase 1
Completed
Conditions
Oral Helicobacter Pylori
Interventions
Drug: Mouth washing
First Posted Date
2013-05-29
Last Posted Date
2013-05-29
Lead Sponsor
Ameritek USA
Target Recruit Count
350
Registration Number
NCT01863823
Locations
🇨🇳

Beijing University First Hospital, Beijiang, China

Surgical Treatment of Peri-implantitis

Phase 4
Completed
Conditions
Peri-Implantitis
Interventions
Drug: Saline
First Posted Date
2013-05-20
Last Posted Date
2014-11-13
Lead Sponsor
Göteborg University
Target Recruit Count
100
Registration Number
NCT01857804
Locations
🇸🇪

Department of Periodontology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants

Phase 1
Completed
Conditions
Dental Implants
Interventions
First Posted Date
2013-05-10
Last Posted Date
2017-05-04
Lead Sponsor
Université de Montréal
Target Recruit Count
42
Registration Number
NCT01851681
Locations
🇨🇦

Université de Montréal - Faculty of Dentistry - Dental clinics, Montreal, Quebec, Canada

Antibiotic Prophylaxis - Amoxicillin

Phase 3
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-04-11
Last Posted Date
2016-09-02
Lead Sponsor
Bodil Lund
Target Recruit Count
29
Registration Number
NCT01829529
Locations
🇸🇪

Karolinska University Hospital. Department of Dental Medicine, Stockholm, Huddinge, Sweden

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

First Posted Date
2013-03-28
Last Posted Date
2015-05-29
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
96
Registration Number
NCT01820026
Locations
🇮🇹

Manuela Merli, Rome, Italy

Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

Phase 4
Completed
Conditions
Helicobacter Infections
Interventions
Drug: tripotassium dicitrate bismuthate
First Posted Date
2013-02-15
Last Posted Date
2013-02-15
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
648
Registration Number
NCT01792700
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Phase 4
Completed
Conditions
Cure Rate of Helicobacter Pylori Infection
Interventions
Drug: Proton pump inhibitor
First Posted Date
2012-12-05
Last Posted Date
2014-08-29
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
200
Registration Number
NCT01742429
Locations
🇨🇳

Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China

Empirical Rescue Therapies of Helicobacter Pylori Infection

Phase 4
Completed
Conditions
Functional Dyspepsia
Scarred Peptic Ulcer
Interventions
Drug: Proton Pump Inhibitor
Drug: Bismuth
First Posted Date
2012-08-20
Last Posted Date
2013-06-04
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
424
Registration Number
NCT01668927
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

Phase 4
Completed
Conditions
Functional Dyspepsia
Peptic Ulcer
Interventions
Drug: Bismuth
Drug: Levofloxacin
First Posted Date
2012-08-17
Last Posted Date
2012-12-13
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
161
Registration Number
NCT01667718
Locations
🇨🇳

Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy